GlassScriptPhysician profile
Robert V Jao
NPI 1285707547
$27,795.89
in general payments reported to CMS, 2019-2025
33 companies · $3,547 in 2025
The $3,547 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $1,969 · 2021: $1,247 · 2022: $2,305 · 2023: $2,742 · 2024: $2,755 · 2025: $3,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,256 · Travel and Lodging: $712 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,255.99 |
| Travel and Lodging | $712.23 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $10,625.82 | 2019-2025 | Livdelzi, Vemlidy |
| Pfizer INC. | $6,927.01 | 2019-2025 | |
| Abbvie INC. | $3,846.46 | 2019-2025 | |
| Boston Scientific Corporation | $1,047.38 | 2023-2025 | Resolution Clip, Overstitch Endoscopic Suturing System |
| Janssen Biotech, INC. | $771.42 | 2019-2025 | Tremfya, Stelara, Simponi |
| E.R. Squibb & Sons, L.L.C. | $657.47 | 2019-2025 | Opdivo, Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $597.40 | 2019-2025 | Entyvio, Gattex |
| Madrigal Pharmaceuticals | $398.51 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $375.88 | 2020-2024 | Ocaliva |
| Celltrion USA INC. | $306.02 | 2024-2025 | Zymfentra, Vegzelma |
| Allergan, INC. | $290.78 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $288.85 | 2024-2025 | Tremfya |
| Aimmune Therapeutics, INC. | $226.21 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $186.21 | 2022-2023 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $168.57 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $137.59 | 2024 | Givlaari |
| Apollo Endosurgery US INC | $131.22 | 2023 | Overstitch Endoscopic Suturing System |
| Nestle Healthcare Nutrition INC. | $129.91 | 2021-2023 | |
| Regeneron Pharmaceuticals, INC. | $128.70 | 2023 | Dupixent |
| Novo Nordisk INC | $124.89 | 2025 | |
| Cook Medical LLC | $92.75 | 2025 | Hemospray |
| Biocon Biologics INC | $42.64 | 2025 | Yesintek |
| Enterra Medical, INC. | $41.55 | 2024 | |
| Celgene Corporation | $41.34 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $33.46 | 2025 | Voquezna |
| Pharmacosmos Therapeutics INC. | $26.94 | 2021 | |
| Orphalan INC | $26.89 | 2024 | Cuvrior |
| Regeneron Healthcare Solutions, INC. | $23.93 | 2022 | |
| Exact Sciences Corporation | $23.71 | 2025 | The Cologuard Plus Collection Kit |
| Micro-Tech Endoscopy USA, INC. | $23.24 | 2024 | Dat Device |
| Bayer Healthcare Pharmaceuticals INC. | $21.16 | 2019 | |
| Mirum Pharmaceuticals, INC. | $19.09 | 2022 | |
| Omeros Corporation | $12.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Jao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.